8-K: Calidi Biotherapeutics Increases At-The-Market Offering to $11.2 Million

Calidi Biotherapeutics increases its at-the-market offering with Ladenburg Thalmann & Co. Inc. to a maximum aggregate of $11.2 million.

Summary

• Calidi Biotherapeutics increased the maximum aggregate offering amount of its common stock under the At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc.
• The offering amount increased from $5,100,000 to $11,200,000.
• A prospectus supplement was filed for an aggregate of $6,100,000.
• Prior to this, the company had already sold approximately $5,000,000 worth of common stock under the Sales Agreement.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard financial transaction. The increase in offering size could be seen as a positive (more capital) or negative (dilution) depending on the investor's perspective.

Positives

• The increased offering provides Calidi Biotherapeutics with additional capital.

Risks

• The increased offering could dilute existing shareholders' equity.

Future Outlook

The company intends to continue offering and selling shares of common stock through the Agent under the Sales Agreement.

Industry Context

At-the-market offerings are a common way for biotech companies to raise capital, especially when they need funding for research and development or clinical trials.

Key Dates